Treatment Information

Back

Lung Cancer treatment details. Chemotherapy, Biologic therapy.

Doce de Octobre University Hospital, Madrid, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:5City/State/Province:Madrid
Treatments:Chemotherapy, Biologic therapyHospital:Doce de Octobre University Hospital
Drugs:Journal:Link
Date:Mar 2006

Description:

Patients: This Phase III study involved 670 patients with advanced non-small-cell lung cancer. None of the patients had received treatment before the study. The patients were randomly divided into two groups. Group B had 342 patients (222 men, 120 women, median age 59) with the following demographics: 51 Asian, 13 Hispanic, 276 Caucasian).

Treatment: Treatment consisted of two chemotherapeutic agents: gemcitabine and cisplatin. In addition, Group B received aprinocarsen, which is an antisense oligonucleotide targetting the enzyme protein kinase C.

Toxicity: For Group B, two patients died due to adverse toxicity. In addition, grade 3-4 toxicities included neutropenia, thrombocytopenia, leukopenia, anemia, vomiting, fatigue, nausea, thrombosis and embolism.

Results: The median overall survival was 10.4 months for Group A and 10.0 months for Group B; this difference was not statistically significant. The authors concluded, "Adding aprinocarsen to gemcitabine and cisplatin regimen did not enhance survival and other efficacy measures in patients with advanced NSCLC."

Support: Eli Lilly and Company financially supported this study. Eli Lilly manufactures and/or markets gemcitabine and aprinocarsen.

Correspondence: Luis Paz-Ares



Back